CTCBIO Inc. (KOSDAQ:060590)
South Korea · Delayed Price · Currency is KRW 3,705.00
-190.00 (-4.88%)
At close: Apr 2, 2026
CTCBIO Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 123,769 | 119,877 | 137,878 | 165,206 | 140,318 |
Other Revenue | -0 | -0 | -0 | -0 | -0 |
| 123,769 | 119,877 | 137,878 | 165,206 | 140,318 | |
Revenue Growth (YoY) | 3.25% | -13.06% | -16.54% | 17.74% | 7.91% |
Cost of Revenue | 73,810 | 70,644 | 95,309 | 111,150 | 107,228 |
Gross Profit | 49,959 | 49,232 | 42,570 | 54,056 | 33,090 |
Selling, General & Admin | 42,172 | 48,280 | 41,894 | 37,191 | 31,962 |
Research & Development | 1,785 | 3,558 | 2,639 | 2,414 | 3,090 |
Amortization of Goodwill & Intangibles | 66.17 | 81.93 | 96.74 | 296.67 | 414.05 |
Other Operating Expenses | 270.06 | 317.14 | 264.6 | 208.57 | 231.86 |
Operating Expenses | 43,709 | 54,246 | 47,148 | 42,826 | 36,027 |
Operating Income | 6,250 | -5,014 | -4,578 | 11,230 | -2,938 |
Interest Expense | -2,317 | -2,846 | -3,244 | -2,895 | -3,647 |
Interest & Investment Income | 307.85 | 520.97 | 725.08 | 251.11 | 118.76 |
Currency Exchange Gain (Loss) | -1,382 | 996.66 | 41.68 | -470.14 | -533.35 |
Other Non Operating Income (Expenses) | 66.55 | 1,771 | 689.17 | -2,374 | 1,952 |
EBT Excluding Unusual Items | 2,925 | -4,571 | -6,367 | 5,741 | -5,047 |
Gain (Loss) on Sale of Investments | - | -186.4 | -201.64 | -320.2 | -708.55 |
Gain (Loss) on Sale of Assets | 321.68 | 137.86 | 264.89 | -40.55 | 1.28 |
Asset Writedown | -268.5 | -689.52 | -9,411 | -5,181 | -1,337 |
Other Unusual Items | - | - | - | 0.01 | -595.12 |
Pretax Income | 2,978 | -5,309 | -15,715 | 199.42 | -7,687 |
Income Tax Expense | -289.6 | -102.59 | -126.83 | -4,504 | 291.74 |
Earnings From Continuing Operations | 3,268 | -5,206 | -15,588 | 4,704 | -7,978 |
Earnings From Discontinued Operations | -27.15 | -14.05 | - | - | - |
Net Income to Company | 3,241 | -5,220 | -15,588 | 4,704 | -7,978 |
Minority Interest in Earnings | - | - | - | - | 660.21 |
Net Income | 3,241 | -5,220 | -15,588 | 4,704 | -7,318 |
Net Income to Common | 3,241 | -5,220 | -15,588 | 4,704 | -7,318 |
Shares Outstanding (Basic) | 24 | 24 | 24 | 24 | 22 |
Shares Outstanding (Diluted) | 24 | 24 | 24 | 24 | 22 |
Shares Change (YoY) | -0.50% | 0.16% | 0.38% | 7.17% | 11.67% |
EPS (Basic) | 136.00 | -218.00 | -651.97 | 197.49 | -329.29 |
EPS (Diluted) | 136.00 | -218.00 | -652.00 | 197.00 | -329.29 |
Free Cash Flow | 3,597 | 2,357 | 6,331 | 15,051 | 4,783 |
Free Cash Flow Per Share | 150.95 | 98.42 | 264.80 | 631.92 | 215.23 |
Gross Margin | 40.37% | 41.07% | 30.88% | 32.72% | 23.58% |
Operating Margin | 5.05% | -4.18% | -3.32% | 6.80% | -2.09% |
Profit Margin | 2.62% | -4.35% | -11.31% | 2.85% | -5.21% |
Free Cash Flow Margin | 2.91% | 1.97% | 4.59% | 9.11% | 3.41% |
EBITDA | 12,781 | 891.05 | 1,368 | 17,936 | 3,344 |
EBITDA Margin | 10.33% | 0.74% | 0.99% | 10.86% | 2.38% |
D&A For EBITDA | 6,532 | 5,905 | 5,947 | 6,706 | 6,282 |
EBIT | 6,250 | -5,014 | -4,578 | 11,230 | -2,938 |
EBIT Margin | 5.05% | -4.18% | -3.32% | 6.80% | -2.09% |
Advertising Expenses | 1,061 | 1,175 | 1,055 | 636.46 | 722.54 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.